Added to YB: 2026-05-01
Pitch date: 2026-04-30
WVE [neutral]
Wave Life Sciences, Inc.
-35.17%
current return
Author Info
No bio for this author
Company Info
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health.
Market Cap
$947.8M
Pitch Price
$7.08
Price Target
25.00 (+445%)
Dividend
N/A
EV/EBITDA
-2.45
P/E
-4.47
EV/Sales
7.66
Sector
Pharmaceuticals
Category
growth
WVE Q1 2026. RNA Editing Platform Hits Inflection.
WVE (update): Q1 loss -44% YoY to $26.1M on GSK collab rev $38.2M. $544.6M cash into 3Q28. 4 programs w/ 2026 catalysts: WVE-007 obesity P2a Q2 (5.3% fat loss, 14.3% visceral fat↓, 1-2x/yr dosing); WVE-006 AATD accel approval feedback mid-26, May 18 ATS/May 29 EASL data; WVE-N531 DMD NDA 2026. Median PT $25 vs $7.07. Near-term catalysts: May ATS, mid-yr FDA feedback, P2a start.
Read full article (3 min)